Gridelli C, Ianniello G P, Maiorino A, Curcio C, D'Aprile M, Brancaccio L, Palmeri S, Gentile M, Comella G, Pedicini T
Cattedra di Oncologia Medica, II Fac. Med. e Chir., Università di Napoli, Italy.
Am J Clin Oncol. 1994 Apr;17(2):160-2. doi: 10.1097/00000421-199404000-00014.
In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent "split-course" chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5% objective responses (OR) with 52.5% complete responses (CR), a median survival of 14 months, with 13% long-term survivors at 30 months. In extensive disease we obtained 83.6% OR with 28.5% CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.
在我们的研究中，72例小细胞肺癌患者，其中23例为局限期，49例为广泛期，接受了卡铂、表柔比星和依托泊苷（CEV）化疗（第1天卡铂300mg/m²，第1天表柔比星50mg/m²，第1 - 3天依托泊苷100mg/m²静脉滴注，每4周一次）。局限期患者还接受了同步“分割疗程”胸部放疗，若诊断时非ⅢB期，对治疗有反应者随后接受手术。在局限期，我们获得了96.5%的客观缓解率（OR），其中52.5%为完全缓解（CR），中位生存期为14个月，30个月时13%为长期存活者。在广泛期，我们获得了83.6%的OR，28.5%的CR，中位生存期为10个月。毒性主要为可控的骨髓抑制，尤其是局限期患者。这些数据表明CEV化疗方案具有高活性。
